AbbVie's Rinvoq Bolsters Its Potential In Atopic Dermatitis
JAK1 Inhibitor ‘Clears’ Second Of Three Phase III AD Trials
AbbVie's Rinvoq has performed well in the second of three Phase III studies evaluating its potential treatment for atopic dermatitis, further boosting chances the JAK1 inhibitor will become a blockbuster in that indication.
You may also be interested in...
AbbVie reported revenue growth during the second quarter, with products like Rinvoq and Skyrizi leading the charge. But Allergan, despite growth for Vraylar and Ubrelvy, pushed down overall performance.
The merger closed in May, so the second quarter earnings report will be the first presentation of the combined company’s performance and outlook.
Novo Nordisk said it extended its global lead in the GLP-1 space during Q2 and outlined a strategy to dominate the growing market obesity market as its pipeline grows.